TeamDrive
RUS

Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

22 June 2015

June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

Full video is published at Vedomodsti web-site

According to Leonid Melamed, “The time of uncertainty is exactly the time when management should make important decisions both tactical and strategical that are usually postponed in other times or at least realized in a milder way. This is the right time to allocate internal resources aimed to ensure competitive advantages and to cut down the resources spent on the products, processes and areas that do not bring any competitive value in tactical viewpoint. Such periods are the time to reallocate strategic investments in something that will provide competitive value in 3 to 5 years when stability will come in place of uncertainty. Business model also must be changed, if necessary.

In other words, hard times create a welcomed opportunity for drastic changes that were difficult to realize under regular circumstances.”

In hard times, each business unit of the company is a key point. Such circumstances act as a rich soil to grow brilliant ideas and define the company’s future development. And only highly coordinated operation of all business units may lead the company to a success.

The Vedomosti’s FocusForum Conference will take place June 25, 2015, and bring together various experts who will share their ideas and valuable experience and try to identify an action plan for the future. General Managers, Heads of Business Development, HR, Marketing, Advertising and PR will introduce their business cases and strategies during panel discussions, presentations and unofficial personal meetings.

FocusForum web-site


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more